JPWO2023081689A5 - - Google Patents

Info

Publication number
JPWO2023081689A5
JPWO2023081689A5 JP2024525233A JP2024525233A JPWO2023081689A5 JP WO2023081689 A5 JPWO2023081689 A5 JP WO2023081689A5 JP 2024525233 A JP2024525233 A JP 2024525233A JP 2024525233 A JP2024525233 A JP 2024525233A JP WO2023081689 A5 JPWO2023081689 A5 JP WO2023081689A5
Authority
JP
Japan
Prior art keywords
polynucleotide
nucleotides
seq
sequence
inventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542995A (ja
JP2024542995A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079124 external-priority patent/WO2023081689A2/en
Publication of JP2024542995A publication Critical patent/JP2024542995A/ja
Publication of JPWO2023081689A5 publication Critical patent/JPWO2023081689A5/ja
Publication of JP2024542995A5 publication Critical patent/JP2024542995A5/ja
Pending legal-status Critical Current

Links

JP2024525233A 2021-11-03 2022-11-02 ゲノム編集のためのポリヌクレオチド、組成物、及び方法 Pending JP2024542995A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275425P 2021-11-03 2021-11-03
US63/275,425 2021-11-03
US202263352158P 2022-06-14 2022-06-14
US63/352,158 2022-06-14
PCT/US2022/079124 WO2023081689A2 (en) 2021-11-03 2022-11-02 Polynucleotides, compositions, and methods for genome editing

Publications (3)

Publication Number Publication Date
JP2024542995A JP2024542995A (ja) 2024-11-19
JPWO2023081689A5 true JPWO2023081689A5 (https=) 2025-11-12
JP2024542995A5 JP2024542995A5 (https=) 2025-11-12

Family

ID=84537879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525233A Pending JP2024542995A (ja) 2021-11-03 2022-11-02 ゲノム編集のためのポリヌクレオチド、組成物、及び方法

Country Status (12)

Country Link
US (1) US20240301377A1 (https=)
EP (1) EP4426822A2 (https=)
JP (1) JP2024542995A (https=)
KR (1) KR20240114296A (https=)
AU (1) AU2022382975A1 (https=)
CA (1) CA3237303A1 (https=)
CL (1) CL2024001332A1 (https=)
CO (1) CO2024007019A2 (https=)
IL (1) IL312508A (https=)
MX (1) MX2024005242A (https=)
TW (1) TW202325848A (https=)
WO (1) WO2023081689A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12401411B2 (en) * 2020-05-08 2025-08-26 Telefonaktiebolaget Lm Ericsson (Publ) Versatile AAS receiver
WO2021228349A1 (en) 2020-05-11 2021-11-18 Telefonaktiebolaget Lm Ericsson (Publ) Efficient prach scheduling
WO2025081064A2 (en) * 2023-10-11 2025-04-17 Illumina, Inc. Thermophilic deaminase and methods for identifying modified cytosine
WO2025137301A1 (en) * 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Methods for rapid engineering of cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
US6169169B1 (en) 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
TWI773666B (zh) 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
WO2018067447A1 (en) 2016-10-03 2018-04-12 Itellia Therapeutics, Inc. Improved methods for identifying double strand break sites
CA3057192A1 (en) * 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
PT3688162T (pt) 2017-09-29 2024-04-23 Intellia Therapeutics Inc Formulações
AR113154A1 (es) 2017-09-29 2020-01-29 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para edición del genoma
AU2018364993B2 (en) 2017-11-10 2022-10-06 University Of Massachusetts Targeted CRISPR delivery platforms
EP3850088A4 (en) * 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
WO2020072605A1 (en) 2018-10-02 2020-04-09 Intellia Therapeutics, Inc. Ionizable amine lipids
BR112021007123A2 (pt) 2018-10-15 2021-08-10 University Of Massachusetts edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase
IL314386A (en) 2018-12-05 2024-09-01 Intellia Therapeutics Inc amine modified lipids
BR112021019224A2 (pt) 2019-03-28 2021-11-30 Intellia Therapeutics Inc Polinucleotídeos, composições e métodos para expressão de polipeptídeo
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
AU2020293211B2 (en) * 2019-06-11 2026-03-05 Pairwise Plants Services, Inc. Methods of producing plants with altered fruit development and plants derived therefrom
CN114616002A (zh) * 2019-09-13 2022-06-10 瑞泽恩制药公司 使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
CR20230305A (es) * 2020-12-11 2023-11-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación

Similar Documents

Publication Publication Date Title
CN110291198B (zh) 经修饰的指导rna
JP2025063317A5 (https=)
Haffar et al. The matrix protein gene sequence analysis reveals close relationship between peste des petits ruminants virus (PPRV) and dolphin morbillivirus
JP2021522783A5 (https=)
BR112019015244A2 (pt) ácidos nucleicos codificando proteínas associadas a crispr e usos dos mesmos
JPS60500796A (ja) 植物細胞での発現に適したキメラ遺伝子
US12129478B1 (en) Engineered adenosine deaminases and base editors thereof
JP2002503459A5 (https=)
Jeeva et al. Crimean-Congo hemorrhagic fever virus nucleocapsid protein augments mRNA translation
JPWO2023283092A5 (https=)
KR20230007218A (ko) 초소형 염기교정 시스템 및 이의 용도
CN119421716A (zh) 用于环状rna亲和纯化的组合物和方法
US9809632B2 (en) Universal protein tag for double stranded nucleic acid delivery
CN112708605A (zh) 一个Cas9蛋白拆分得到的蛋白组及其应用
JPWO2022125968A5 (https=)
JPWO2023081689A5 (https=)
JPWO2023039378A5 (https=)
IL303892A (en) In vitro assembly of RNA-encapsulating enalavirus capsids
JPS5951793A (ja) 新規クロ−ニングビヒクル
JPS6047683A (ja) プロモ−タ−
WO2025081541A1 (zh) 非天然rna的制备方法及产品
KR20240141024A (ko) E1347A DddAtox 변이체-TnpB fusion 단백질을 이용한 유전자 가위 시스템
TW202246510A (zh) 以crispr/slucas9治療第1型肌強直性營養不良之組合物及方法
JPWO2022204093A5 (https=)
CN114457077A (zh) 靶向新型冠状病毒rna及其反义链utr的脱氧核酶及其应用